125 related articles for article (PubMed ID: 23391649)
1. [Myeloproliferative neoplasms].
Komatsu N
Rinsho Ketsueki; 2013 Jan; 54(1):71-8. PubMed ID: 23391649
[No Abstract] [Full Text] [Related]
2. [JAK2 inhibitors in the treatment of myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2012 Oct; 53(10):1600-7. PubMed ID: 23037732
[No Abstract] [Full Text] [Related]
3. [Molecular biology and new drug therapy for myeloproliferative neoplasm].
Kitanaka A; Shide K; Shimoda K
Rinsho Ketsueki; 2013 Oct; 54(10):1697-703. PubMed ID: 24064819
[No Abstract] [Full Text] [Related]
4. JAK inhibition: the key to treating myeloproliferative neoplasm?
Tibes R; Bogenberger JM; Mesa RA
Expert Rev Hematol; 2012 Dec; 5(6):583-5. PubMed ID: 23216589
[No Abstract] [Full Text] [Related]
5. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Girsberger S; Karow A; Lundberg P; Dirnhofer S; Lehmann T; Passweg JR; Tichelli A; Skoda R; Rovó A
Acta Haematol; 2013; 129(1):23-5. PubMed ID: 23006959
[No Abstract] [Full Text] [Related]
6. Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm.
Ayyalu TK; Issa M
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28801515
[No Abstract] [Full Text] [Related]
7. Loss of S-100-positive Schwann cells is a feature of JAK2 V617F-positive myeloproliferative neoplasm.
Bihari C; Rastogi A; Saxena P; Kumar A
Ann Hematol; 2015 Aug; 94(8):1427-9. PubMed ID: 25968911
[No Abstract] [Full Text] [Related]
8. Janus kinase 2 inhibitors in myeloproliferative disorders.
Lucia E; Recchia AG; Gentile M; Bossio S; Vigna E; Mazzone C; Madeo A; Morabito L; Gigliotti V; De Stefano L; Caruso N; Servillo P; Franzese S; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Jan; 20(1):41-59. PubMed ID: 21128825
[TBL] [Abstract][Full Text] [Related]
9. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
[TBL] [Abstract][Full Text] [Related]
10. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms.
Verstovsek S
J Clin Oncol; 2011 Mar; 29(7):781-3. PubMed ID: 21220594
[No Abstract] [Full Text] [Related]
11. Myeloproliferative neoplasms: an overview.
Finnegan K
Clin Lab Sci; 2011; 24(3):178-82. PubMed ID: 21905584
[No Abstract] [Full Text] [Related]
12. Myeloproliferative neoplasms: the role of molecular markers.
Collins L
Clin Lab Sci; 2011; 24(3):183-6. PubMed ID: 21905585
[No Abstract] [Full Text] [Related]
13. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
14. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
15. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
Malysz J; Crisan D
Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
18. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
19. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
20. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
